GSK plc
Stocks generating the largest moves midday: Starbucks, CarMax, Virgin Galactic and far more
A watch of the Starbucks vending van in the course of its debut in Hangzhou, the capital of China’s Zhejiang province, June 7, 2022. Long Wei | Future Publishing | Getty Photos Examine out the organizations generating headlines in midday investing. Starbucks — Starbucks shares dropped almost 3% just after a union representing employees explained […]
Read More
Pfizer, GSK RSV shots for older adults may prevent thousands of hospitalizations, CDC analysis says
Respiratory syncytial virus vial. Manjurul | Istock | Getty Images Vaccinating one million adults ages 65 and above with a single RSV shot from Pfizer or GSK may prevent thousands of hospitalizations over two seasons of the virus, according to a Centers for Disease Control and Prevention analysis. A CDC medical officer presented the analysis, […]
Read More
CDC advisory panel backs use of GSK and Pfizer RSV vaccines in adults 60 and older
A health worker prepares a flu vaccine shot before administering it to a local resident in Los Angeles, the United States, on Dec. 17, 2022. Xinhua News Agency | Getty Images An advisory committee to the Centers for Disease Control and Prevention on Wednesday recommended that adults ages 60 and above, after consulting their doctors, […]
Read More
Stocks producing the largest moves midday: Dollar Tree, Amazon, FedEx and far more
People today walk by a Dollar Tree retail outlet in the Brooklyn borough of New York Town, December 11, 2018. Spencer Platt | Getty Illustrations or photos News | Getty Images Verify out the organizations producing headlines in midday buying and selling. Amazon — Shares of the on the internet retail big slumped 1.3% following […]
Read More
GSK says RSV vaccine for older adults provides protection over two seasons
Respiratory syncytial virus viral vaccine under research. Hailshadow | Istock | Getty Images GlaxoSmithKline on Wednesday said its vaccine to protect adults ages 60 and older from respiratory syncytial virus, or RSV, remained effective across two seasons of the disease. A single dose of the shot was 67.2% effective in preventing lower respiratory tract illness […]
Read More
Pfizer RSV vaccine for older adults is only slightly less effective after 18 months
Respiratory syncytial virus – viral vaccine under research Hailshadow | Istock | Getty Images Pfizer‘s vaccine that protects adults ages 60 and older from respiratory syncytial virus was slightly less effective after 18 months, according to clinical trial results the company announced Wednesday. The data is from New York-based Pfizer’s clinical trial on more than […]
Read More
Musk’s Neuralink valued at about $5 billion even with extended road to marketplace: Reuters
Jonathan Raa | Nurphoto | Getty Images Elon Musk’s mind implant startup Neuralink, which was valued at near to $2 billion in a private fundraising spherical two a long time in the past, is now value all around $5 billion dependent on privately executed inventory trades described to Reuters by 5 sources with understanding of […]
Read More
FDA approves Pfizer RSV vaccine for older adults
Luis Alvarez | Digitalvision | Getty Images The Food and Drug Administration on Wednesday approved a vaccine made by Pfizer that protects adults ages 60 and older from respiratory syncytial virus, a common pathogen that kills and hospitalizes thousands of seniors every year. Pfizer, in a statement Wednesday, said it expects to have supply available […]
Read More
FDA advisors recommend Pfizer’s RSV vaccine for infants but raise safety concerns
Respiratory syncytial virus – viral vaccine under research Hailshadow | Istock | Getty Images The Food and Drug Administration’s independent panel of advisors on Thursday recommended full approval of Pfizer’s vaccine that protects infants from RSV, but raised safety concerns over premature births that may be tied to the shot. The committee unanimously said the […]
Read More
Pfizer RSV vaccine for infants has ‘generally favorable’ safety data, FDA staff say
Blood sample for respiratory syncytial virus (RSV) test Jarun011 | Istock | Getty Images U.S. Food and Drug Administration staff on Tuesday said Pfizer’s vaccine that protects infants from respiratory syncytial virus has “generally favorable” safety data. The FDA staff made the conclusion in briefing documents ahead of a meeting on Thursday, when a panel […]
Read More